Value-Based Insurance Design at Onex Custom Case Solution & Analysis

Evidence Brief: Value-Based Insurance Design at Onex

1. Financial Metrics

• Healthcare Cost Inflation: Portfolio companies faced annual premiums increasing at 8-12 percent, significantly outpacing general inflation and revenue growth.
• Chronic Disease Impact: Approximately 20-25 percent of the employee population accounted for over 75 percent of total healthcare spend, primarily driven by diabetes, hypertension, and asthma.
• Co-pay Structure: Standard plans required 20-40 dollar co-pays for specialist visits and 15-50 dollar tiers for maintenance medications.
• Potential Savings: Actuarial estimates suggested that for every 1 dollar spent on eliminating co-pays for high-value chronic medications, the firm could avoid 3.50 to 5.00 dollars in emergency room and hospitalization costs over a 3-year horizon.

2. Operational Facts

• Portfolio Diversity: Onex managed companies across manufacturing, services, and technology, each with distinct demographic profiles and existing Third-Party Administrator (TPA) contracts.
• VBID Mechanism: The program focused on clinical nuance, lowering barriers to high-value services while maintaining or increasing barriers to low-value services.
• Data Integration: Claims data was fragmented across multiple insurers, making a unified health-risk assessment difficult across the entire portfolio.
• Administrative Load: Implementing VBID required renegotiating pharmacy benefit manager (PBM) contracts to allow for zero-dollar co-pay tiers.

3. Stakeholder Positions

• Onex Leadership: Viewed healthcare costs as a direct drag on EBITDA and eventual exit multiples.
• Portfolio Company CEOs: Expressed concern regarding the short-term increase in pharmacy spend before long-term medical savings materialized.
• Employees: Historically skeptical of benefits changes, often perceiving them as cost-shifting maneuvers rather than health improvements.
• Third-Party Administrators: Reluctant to customize plan designs due to the administrative complexity of tracking value-based outcomes versus simple volume.

4. Information Gaps

• Adherence Elasticity: The case lacks specific data on how much medication adherence would actually increase once co-pays reached zero for this specific demographic.
• Exit Timing: No data provided on the average remaining holding period for current portfolio companies, which is critical for ROI realization.
• Provider Quality: Absence of a mechanism to steer employees toward high-quality providers even if the insurance design was optimized.

Strategic Analysis

1. Core Strategic Question

• How can Onex institutionalize a healthcare procurement strategy that reduces long-term medical liabilities without compromising short-term cash flow or talent retention across a decentralized portfolio?

2. Structural Analysis

The healthcare value chain for Onex is currently broken. Portfolio companies act as passive payers in a system where providers and insurers benefit from volume rather than outcomes. Applying a Value Chain Analysis reveals that healthcare spending is a significant non-core expense that directly reduces the net present value of the assets. The Jobs-to-be-Done for Onex is not providing insurance, but ensuring a productive, healthy workforce at the lowest sustainable cost. VBID shifts the focus from cost-shifting (increasing deductibles) to cost-optimization (investing in prevention).

3. Strategic Options

4. Preliminary Recommendation

Onex should implement a mandatory VBID framework for all portfolio companies with over 1,000 US employees, targeting the top three chronic conditions: diabetes, hypertension, and coronary artery disease. This approach targets the 20 percent of employees driving 75 percent of costs. The immediate increase in pharmacy spend is a necessary investment to stabilize the medical loss ratio (MLR) ahead of company exits. This is a financial decision disguised as a benefits change.

Implementation Roadmap

1. Critical Path

• Month 1-2: Data Aggregation. Harmonize claims data across all TPAs to identify the specific chronic disease burden per portfolio company.
• Month 3: PBM Renegotiation. Update formularies to include zero-dollar co-pays for essential maintenance drugs.
• Month 4: Executive Alignment. Conduct workshops with portfolio CFOs to adjust budget expectations for the initial pharmacy spend spike.
• Month 5-6: Enrollment and Communication. Launch the Healthy Onex initiative, emphasizing improved health outcomes rather than insurance changes.

2. Key Constraints

• Administrative Friction: TPAs often lack the technical agility to implement nuanced co-pay structures quickly.
• Holding Period Mismatch: If a company is slated for exit within 12 months, the VBID investment may not be fully recovered by Onex, though it may increase the sale price by demonstrating a managed cost trajectory.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of a short-term cash drain, the rollout will utilize a phased approach. Year 1 will focus exclusively on medication adherence for the most expensive 5 percent of claimants. Year 2 will expand to specialist visit co-pay waivers for high-value providers. This ensures that the most certain ROI is captured first, providing the proof of concept needed to maintain stakeholder buy-in.

Executive Review and BLUF

1. BLUF

Approve the immediate implementation of Value-Based Insurance Design (VBID) across the US portfolio. Healthcare costs currently represent an unmanaged liability that erodes EBITDA. Traditional cost-shifting via higher deductibles has failed; it encourages employees to defer essential care, leading to expensive acute episodes. By eliminating co-pays for high-value chronic treatments, Onex will reduce total medical spend by an estimated 15 percent over three years. This move directly increases exit multiples by stabilizing labor costs and demonstrating sophisticated operational management to future buyers.

2. Dangerous Assumption

The analysis assumes that removing financial barriers (co-pays) is sufficient to change patient behavior. It ignores non-financial barriers such as health literacy, transportation, and time constraints that also prevent medication adherence and lead to costly hospitalizations.

3. Unaddressed Risks

• Adverse Selection: A superior benefits package might attract higher-risk talent from competitors, potentially neutralizing the per-capita savings through a higher baseline risk pool.
• PBM Rebate Loss: Moving toward zero-dollar co-pays for specific high-value drugs may conflict with existing PBM rebate contracts that favor higher-cost, lower-value alternatives.

4. Unconsidered Alternative

The team did not evaluate the creation of an Onex-owned captive insurance entity. By self-insuring the entire portfolio through a single captive, Onex could capture the underwriting profit currently kept by commercial insurers and gain total control over data and plan design without negotiating with external TPAs.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW